Antimicrobial susceptibility of Streptococcus agalactiae in a Maternal and Child Hospital in Lima, Peru. 2015-2020

Authors

DOI:

https://doi.org/10.20453/rmh.v33i3.4340

Keywords:

Streptococcus agalactiae, microbial sensitivity tests, Drug resistance

Abstract

Objective: To determine the antimicrobial susceptibility of Streptococcus agalactiae (GBS) strains isolated between 2015-2020 in a mother-child hospital. Methods: Descriptive study carried out between 2015 and 2020. Antimicrobial identification and susceptibility were determined by the Vitek® 2 automated system. The database obtained was transferred to the WHONET version 5.6 program. 506 GBS isolates are included. Results: 500 (98.8%) were in women. The mean age was 31.9 ± 11.8 years. All were sensitive to penicillin, ampicillin and vancomycin, resistance to erythromycin, clindamycin and levofloxacin was 38.5%, 37.4% and 28%, respectively, showing a resistance peak in 2018. Conclusion: An increase in GBS resistance to antimicrobials was observed, especially in 2018

References

Raabe VN, Shane AL. Group B Streptococcus (Streptococcus agalactiae). Microbiol Spectr. 2019;7(2). Doi: 10.1128/microbiolspec.GPP3-0007-20182. Tayebi Z, Saderi H, Gholami M, Houri H, Samie S, Boroumandi S. Evaluation of Antimicrobial Susceptibility of Streptococcus agalactiae Isolates from Patients with Urinary Tract Infection (UTI) Symptoms. Infect Epidemiol Med. 2016;

(4): 17-19. doi: 10.18869/acadpub.iem.2.4.17

Bolukaoto JY, Monyama CM, Chukwu MO, et al. Antibiotic resistance of Streptococcus agalactiae isolated from pregnant women in Garankuwa, South Africa. BMC Res Notes. 2015; 8:364. doi: 10.1186/s13104-015-1328-0.

Hays C, Louis M, Plainvert C, et al. Changing Epidemiology of Group B Streptococcus Susceptibility to Fluoroquinolones and Aminoglycosides in France. Antimicrob Agents Chemother. 2016; 60(12): 7424-7430. doi: 10.1128/AAC.01374-16

Campelo FA, Pedrosa AC, Antúnez IÁ, Capuz BL. Fenotipos y mecanismos de resistencia a macrólidos y lincosamidas en aislados de Streptococcus agalactiae con significación clínica en un período de ocho años (2002-2010). Rev Esp Quimioter. 2012;25(1):42-6.

Pulido A, Soto J. Incremento de aislamientos de Streptococcus agalactiae en cultivos de orina en un hospital materno-infantil de Lima, Perú. An Fac med. 2019; 80(2): 266-7. doi: 10.15381/anales.802.16427

World Health Organization.WHONET 5: microbiology laboratory database software. Ginebra: World Health Organization; 1999. (Citado el 12 de julio del 2022). Disponible en: https://apps.who.int/iris/handle/10665/66299

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne: Clinical and Laboratory Standards Institute; 2019. (Citado el 12 de julio del 2022). Disponible en: https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf

Hayes K, O’Halloran F, Cotter L. A review of antibiotic resistance in Group B Streptococcus: the story so far. Crit Rev Microbiol. 2020; 46(3):253-269. doi:10.1080/1040841X.2020.1758626

Campo CH, Martínez MF, Otero JC, Rincón G. Prevalencia de colonización vaginorrectal por Streptococcus agalactiae y su perfil de sensibilidad en mujeres embarazadas atendidas en un hospital de tercer nivel. Biomédica. 2019; 39: 689-98. Doi: 10.7705/biomedica.4514

Li C, Sapugahawatte DN, Yang Y, Wong KT, Lo NWS, Ip M. Multidrug-Resistant Streptococcus agalactiae Strains Found in Human and Fish with High Penicillin and Cefotaxime Non-Susceptibilities. Microorganisms. 2020; 8(7): 1055. doi: 10.3390/microorganisms8071055

Abarzúa F, Arias A, García P, et al. Aumento de resistencia de Streptococcus agalactiae vaginal-anal en el tercer trimestre de gestación a eritromicina y clindamicina al cabo de una década de tamizaje universal. Rev chil infectol. 2011; 28(4): 334–337. doi: 10.4067/S0716-10182011000500005.

do Nascimento CS, Dos Santos NFB, Ferreira RCC, Taddei CR. Streptococcus agalactiae in pregnant women in Brazil: prevalence, serotypes, and antibiotic resistance. Braz J Microbiol. 2019; 50(4): 943-952. doi: 10.1007/s42770-019-00129-8

Oviedo P, Pegels E, Laczeski M, Quiroga M, Vergara M. Phenotypic and genotypic characterization of Streptococcus agalactiae in pregnant women. First study in a province of Argentina. Braz J Microbiol. 2013; 44(1): 253- 258. doi: 10.1590/S1517-83822013005000030

Bobadilla FJ, Novosak MG, Cortese IJ, Delgado OD, Laczeski ME. Prevalence, serotypes and virulence genes of Streptococcus agalactiae isolated from pregnant women with 35-37 weeks of gestation. BMC Infect Dis. 2021; 21(1): 73. doi:10.1186/s12879-020-05603-5

Tamariz J, Obregon M, Jara J, Diaz J, Jefferson L, Guerra H. Colonización vaginal y anorectal por Streptococcus agalactiae en gestantes de los Hospitales Nacionales Cayetano Heredia y Arzobispo Loayza. Rev Med Hered. 2004; 15(3): 144-150.

Kawamura Y, Fujiwara H, Mishima N, et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother. 2003; 47(11):3605–3609. doi: 10.1128/AAC.47.11.3605-3609.2003.

Nagano N, Nagano Y, Toyama M, et al. Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1. J Antimicrob Chemother. 2012; 67(4):849–856. doi: 10.1093/jac/dkr546

Francois -Watkins LK, McGee L, et al. Epidemiology of invasive Group B Streptococcal infections among nonpregnant adults in the United States, 2008–2016. JAMA Intern Med. 2019; 179(4):479–488. doi: 10.1001/jamainternmed.2018.7269

Arias B, Kovacec V, Vigliarolo L, et al. Fluoroquinolone-Resistant Streptococcus agalactiae Invasive Isolates Recovered in Argentina. Microb Drug Resist. 2019; 25(5):739-743. doi: 10.1089/mdr.2018.0246

Downloads

Published

2022-11-03

How to Cite

1.
Pulido-Colina A, Soto Pastrana J. Antimicrobial susceptibility of Streptococcus agalactiae in a Maternal and Child Hospital in Lima, Peru. 2015-2020. Rev Méd Hered [Internet]. 2022 Nov. 3 [cited 2024 Apr. 30];33(3):196-200. Available from: https://revistas.upch.edu.pe/index.php/RMH/article/view/4340

Issue

Vol. 33 No. 3 (2022): July - September

Section

BRIEF COMUNICATION

License

Authors assign their rights to the RMH so that may disseminate the article through the means at their disposal. The journal will provide forms of affidavit of authorship and authorization for the publication of the article, which shall be submitted with the manuscript. Authors retain the right to share, copy, distribute, perform and publicly communicate their article, or part of it, mentioning the original publication in the journal.